Double-blinded, Vehicle Controlled Study to Evaluate Efficacy & Tolerance of Bakuchiol and Ethyl Linoleate on Acne

NCT ID: NCT05069272

Last Updated: 2021-10-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-10
• Study Completion Date: 2025-01-30

Brief Summary

Subjects will be assigned to a active cream or vehicle to compare the cosmetic effects. This will take place over a 12 week period.

Conditions

Acne Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Intervention

Synergistic combination of Bakuchiol and Ethyl Linoleate

Group Type: ACTIVE_COMPARATOR

Bakuchiol and Ethyl Linoleate

Intervention Type: OTHER

A synergistic combination of Bakuchiol and Ethyl Linoleate

Vehicle

No active ingredients

Group Type: PLACEBO_COMPARATOR

Vehicle

Intervention Type: OTHER

No actives

Interventions

Bakuchiol and Ethyl Linoleate

A synergistic combination of Bakuchiol and Ethyl Linoleate

Intervention Type: OTHER

Vehicle

No actives

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Healthy female volunteers, aged 18 years or older;
• with mild to moderate acne;
• Subjects must have between 10-100 non-inflammatory lesions and 10-50 inflammatory lesions but no more than 2 nodular lesions and no cysts on their face.
• If applicable, users of estrogens/birth control pills must have been on the treatment regimen for at least 3 months and be willing to continue use for study duration;

Females of child-bearing potential (FCBP): A female is considered not to be of childbearing potential if she is post-menopausal with at least 12 consecutive months of amenorrhea or has undergone surgical sterilization. While on the study, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

• Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR
• Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
• Willing to follow study instructions and available to attend the study visits;
• Willing to provide written informed consent and sign photography release

Exclusion Criteria

• Female subjects: Self-reported pregnant or breast feeding, or planning to become pregnant during the course of the study;
• Known allergy or hypersensitivity to acne treatment products;
• Current skin disease of any type in the test area (e.g. eczema, psoriasis, rosacea, seborrheic dermatitis, vitiligo, etc.), or under the treatment of a doctor for any skin condition;
• Have any cystic acne, acne conglobate, acne fulminans, or secondary acne (chloracne or drug-induced acne) in the test area;
• Any conditions on the test site that would interfere with evaluations (i.e. tattoos, scars, open cuts, sunburn, piercings, excessive hair, etc.);
• Use of topical treatments such as OTC (over the counter) acne medication topical anti-inflammatory medications, salicylic acid, corticosteroids, antibiotics, anti-bacterials, peroxide-containing products, or retinoids within 2 weeks of baseline;
• Use of depigmenting medications such as hydroquinone during the 14 days prior to the study start; Insulin dependent diabetes;
• Concurrent medication that might affect the response to the test articles including routine use of anti-inflammatory medications, anti-histamines, and steroids;
• History of Crohn's disease, or clinically significant enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis);
• Microdermabrasion or laser treatment in the test area within six months of the study;
• Medical condition which, in the opinion of the Investigator, would compromise the safety of the subject or confound study results;
• Use of systemic antibiotics, corticosteroids, antimalarials or oral dapsone within 4 weeks of baseline;
• Use of other anti-acne medications, including isotretinoin or spironolactone, within 6 months of baseline;
• Participation on an investigational drug study within 4 months of the baseline visit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Ratan K. Chaudhuri

INDUSTRY

Sponsor Role: lead

Responsible Party

Ratan K. Chaudhuri

President

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Barrie Drewitt

Role: PRINCIPAL_INVESTIGATOR

Princeton Consumer Research

Locations

Princeton Consumer Research Corp

Chelmsford, England, United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Jack Donnelly

Role: CONTACT

jack@princetonconsumer.com

44(0)1617911797

Terrie Bennett

Role: CONTACT

Terrie@princetonconsumer.com

44(0)1245 934050

Facility Contacts

Terrie Bennett Bennett

Role: primary

44(0)1245 934050

Other Identifiers

SYTPIG1M

Identifier Type: -

Identifier Source: org_study_id